Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    2
    ...
ATC Name B/G Ingredients Dosage Form Price
J01MA12 MATADOR G Levofloxacin - 750mg 750mg Tablet, film coated 1,126,140 L.L
L01AA09 BENDAMUSTINE HYDROCHLORIDE GP PHARM G Bendamustine HCl - 100mg/50ml 100mg/50ml Injectable powder for concentrate for solution 78,439,178 L.L
M01AH05 ETOXA G Etoricoxib - 120mg 120mg Tablet, film coated 398,033 L.L
N05AH03 OLANZAMED G Olanzapine - 5mg 5mg Tablet 665,522 L.L
S01CA01 API-TOBRASON G Dexamethasone - 1mg/g, Tobramycin - 3mg/g Ointment 243,235 L.L
A01AB09 MICOZOLE G Miconazole - 20mg/g 20mg/g Gel 104,820 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 170,630 L.L
C10AA05 TORVALIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,164,664 L.L
G04BE09 VERDA G Vardenafil (HCl) - 10mg 10mg Tablet, orally disintegrating 1,023,880 L.L
J01DC02 CEFORA G Cefuroxime (axetil) - 500mg 500mg Tablet 703,918 L.L
J01MA12 TAVAQUIN G Levofloxacin (hemihydrate) - 750mg 750mg Tablet, film coated 1,389,533 L.L
L01AA09 BENDAMUSTINE MEDAC G Bendamustine HCl - 2.5mg/ml (100mg) 2.5mg/ml Injectable powder for concentrate for solution 16,887,989 L.L
M01AH05 ETOXIB G Etoricoxib - 120mg 120mg Tablet, film coated 425,998 L.L
N02BE01 KIDOL-OR G Paracetamol - 240mg/5ml 240mg/5ml Elixir 314,843 L.L
N05AH03 OLANZAPINE ARROW G Olanzapine - 5mg 5mg Tablet 670,577 L.L
R03BB01 IPRATROPIUM ARROW ADULTES G Ipratropium bromide - 0.5mg/2ml 0.5mg/2ml Inhalation solution for nebuliser 303,708 L.L
A01AB09 MYCOHEAL G Miconazole nitrate - 20mg/g 20mg/g Gel 210,983 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
B05CX01 ALDEX G Dextrose, H2O - 5g/100ml 5g/100ml Injectable solution 182,720 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 25mg 25mg Tablet, coated 1,744,308 L.L
C09CA04 ANDARAN G Irbesartan - 150mg 150mg Tablet, film coated 904,612 L.L
C10AA05 TOVAST G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 2,412,197 L.L
D10AD03 DIFADERM G Adapalene - 0.1% 0.1% Gel 414,671 L.L
J01DC02 CEFUREX G Cefuroxime - 500mg 500mg Tablet 490,503 L.L
L01AA09 BENDAVIVAL G Bendamustine HCl - 100mg 100mg Injectable concentrated powder for solution 26,072,618 L.L
M01AH05 JOSWE COXIT 120 G Etoricoxib - 120mg 120mg Tablet, film coated 517,379 L.L
N02BE01 PAROL CHILDREN G Paracetamol - 240mg/5ml 240mg/5ml Elixir 314,843 L.L
N05AH03 PREXAL 5 G Olanzapine - 5mg 5mg Caplet, film coated 718,956 L.L
S01CA02 LOXTRA G Prednisolone acetate - 2mg/ml, Tetrahydrozoline HCl - 0.4mg/ml, Ofloxacin - 3mg/ml Drops suspension 423,310 L.L
A07AA02 MEDISTAN G Nystatin - 500,000IU 500,000IU Capsule 417,231 L.L
    2
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025